Aprea Therapeutics, Inc. — Form 8-K
Filed November 20, 2026 · analyzed by the 8-K Agent
8-K
▲ Likely positive
significance 72/100
What the filing says
Aprea announced interim Phase 1 results for APR-1051 (WEE1 inhibitor) in 56 patients with advanced solid tumors as of November 1, 2026. Key findings: 1 confirmed partial response (PR) and 1 unconfirmed PR in PPP2R1A-mutated uterine cancer patients; 5 patients with stable disease >4 months; 84% of evaluable patients (21/25) showed ≥50% reduction in pCDK1-Y15 (WEE1 target engagement); 1 dose-limiting toxicity (liver enzyme elevation at 50mg); predominantly Grade 1-2 adverse events. Company plans to enroll ≥50 additional patients in focused cohorts (uterine serous carcinoma and cyclin E-overexpressing platinum-resistant ovarian cancer), with dose escalation completion expected Q2 2027.
Why this rating
Early clinical proof-of-concept with confirmed PR in lead program is material for $8.6M-cap biotech; validates WEE1 target biology, supports continued development. Safety/PK favorable. Meaningful near-term catalyst.
Tradability signal
NO TRADE
No trade: price $0.41 is below our $0.5 floor — spreads at this level eat any edge. (Filing arrived outside market hours — evaluated at the next open with a live quote.)
Derived from this site's own measured outcomes + live price/liquidity at analysis time. An experiment, not investment advice.
Price action (we called it positive)
before filing · preread $0.52 ▲ 15.81% | at our read · unknown $0.45 | +10 min · unknown $0.41 ▼ 8.69% | +30 min · unknown $0.33 ▼ 25.41% | +1 hr · unknown $0.27 ▼ 39.71% | +4 hrs · unknown $0.23 ▼ 47.75% |
The stock had already moved -13.65% between hitting EDGAR and our read finishing — deltas above are measured from our read.
Quotes via Yahoo Finance at capture time; for filings arriving outside market hours the clock starts at the next open. Not investment advice. How accurate are our calls? →
See more from November 20, 2026.
EDGAR·FLOW summarizes public SEC EDGAR filings with automated analysis. Materiality scores and stock-impact predictions are algorithmically generated and are not investment advice. Always verify against the source filing on SEC.gov.